NR3C2

Mineralocorticoid receptor · P08235 · NR3C2 on Sugi Atlas →

103,115 patent compounds predicted against NR3C2, 66,779 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL197733	0.48	11/20
SCHEMBL7132	0.72	10/20
Hydrocortisone Butyrate (SCHEMBL4695)	1.00	8/20
Hydrocortisone Butyrate (SCHEMBL111478)	1.00	8/20
SCHEMBL180224	1.00	8/20
Hydrocortisone Valerate (SCHEMBL80603)	0.97	8/20
Butixocort (SCHEMBL109157)	0.86	8/20
SCHEMBL41083	0.83	8/20
SCHEMBL82865	0.83	8/20
SCHEMBL122186	0.79	8/20
SCHEMBL141635	0.73	8/20
SCHEMBL141636	0.73	8/20
SCHEMBL147438	0.72	8/20
Aldosterone (SCHEMBL1675)	1.00	7/20
Hydrocortisone Probutate (SCHEMBL4778)	0.82	7/20
Hydrocortisone Aceponate (SCHEMBL3697)	0.81	7/20
SCHEMBL142427	0.80	7/20
SCHEMBL122187	0.79	7/20
SCHEMBL7984	0.74	7/20
Prednival (SCHEMBL25387)	0.71	7/20

Clinical trials — most relevant to NR3C2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Tumor Gene Expression in Women With Ovarian Cancer	PHASE4	COMPLETED
Finerenone Plus SGLT2 Inhibitors in Heart Failure	PHASE4	NOT_YET_RECRUITING
How DHEA Supplements Affect Coagulation in Women Using Birth Control Pills	PHASE4	COMPLETED
Effects of the Addition of Metyrapone to Antidepressant Therapy in Depression With Dexamethasone Suppression Test Non-suppression.	PHASE4	UNKNOWN
Mineralocorticoid Use in COVID-19 Patients	PHASE3	COMPLETED
Effects of Advair® in Outpatients With Chronic Obstructive Pulmonary Disease (COPD) Acute Exacerbation	PHASE3	COMPLETED
Impact of the Administration of Fludrocortisone in Very Premature Infants	PHASE2	COMPLETED
Novel Therapeutics in Posttraumatic Stress Disorder (PTSD): A Randomized Clinical Trial of Mifepristone	PHASE2	COMPLETED
Enoxolone in Major Depression - Biomarker-outcome Relationship	PHASE1/PHASE2	RECRUITING
Glucocorticoid Receptor Antagonism in Subclinical Cushings	PHASE1/PHASE2	COMPLETED
Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia	PHASE2	RECRUITING
Fludrocortisone Dose Response Relationship in Septic Shock - FluDReSS	PHASE2	COMPLETED
Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease	EARLY_PHASE1	RECRUITING
Syndromes With Neonatal Salt Loss: Not Only Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency (21OH-ISC)	nan	RECRUITING
Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome	nan	COMPLETED
Effect of Renin Angiotensin Aldosterone System Genetic Polymorphism on the Pharmacological Effect of Mineralocorticoid Receptor Antagonists in Patients With Myocardial Infarction	nan	UNKNOWN
Study of Adrenal Gland Tumors	nan	COMPLETED
Effect of Surgical or Conservative Approach in Patients With Adrenal Incidentalomas	nan	UNKNOWN
RESIST: Understanding the Role of Depression in Heart Disease	nan	COMPLETED
Global Mental Health of Urban Mothers	nan	UNKNOWN
Study on Cutoff Revision Effects and Evaluation of NNT in Primary Aldosteronism	nan	RECRUITING
Multi-level Molecular Profiling of High Acute Stress: a Clinical Study	nan	UNKNOWN
Stress and Treatment Response in Puerto Rican Children With Asthma	nan	COMPLETED
Examining Genetic Differences Among People With 21-Hydroxylase Deficiency	nan	COMPLETED
Evaluation of the Contraceptive Efficacy	nan	COMPLETED
Biomarkers in the Etiology of Idiopathic Intracranial Hypertension	nan	UNKNOWN
Adrenocortical Functions in Women With Nonclassical 21-hydroxylase Deficiency.	nan	UNKNOWN
Overnight Dexamethasone in Primary Aldosteronism Screening	nan	RECRUITING
Safety and Efficacy of DSM 32444 Postbiotic in the Treatment of Acute Rhinosinusitis	nan	COMPLETED
Steroid Treatment of Idiopathic Nephrotic Syndrome	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NR3C2 binder may also engage these)

Protein	Name	Similarity
P22199	—	1.000	P22199 →
Q9N0W8	—	1.000	Q9N0W8 →
Q29131	—	1.000	Q29131 →
Q3YC04	—	1.000	Q3YC04 →
Q4JM28	—	1.000	Q4JM28 →
Q8VII8	—	1.000	Q8VII8 →
Q9N1U3	—	1.000	Q9N1U3 →
Q5R9P5	—	1.000	Q5R9P5 →
Q8AYI2	—	1.000	Q8AYI2 →
Q2KHR2	—	1.000	Q2KHR2 →
Q9Y2X9	—	0.999	Q9Y2X9 →
P70284	—	0.999	P70284 →
Q91573	—	0.999	Q91573 →
P19091	—	0.999	P19091 →
A0A1L8H0H2	—	0.999	A0A1L8H0H2 →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	0.999	landscape →
Q949U2	—	0.999	Q949U2 →
Q499D0	—	0.999	Q499D0 →
Q90655	—	0.998	Q90655 →
Q9PVY9	—	0.998	Q9PVY9 →
Q6PEV8	—	0.998	Q6PEV8 →
Q95267	—	0.998	Q95267 →
P49844	—	0.998	P49844 →
Q7TQG0	—	0.998	Q7TQG0 →
O95677	—	0.998	O95677 →
Q8C0I4	—	0.997	Q8C0I4 →
P06536	—	0.997	P06536 →
Q9R0G7	—	0.997	Q9R0G7 →
P21999	—	0.997	P21999 →
Q28EM1	—	0.997	Q28EM1 →